Photodynamic tumour therapy

FIELD: medicine.

SUBSTANCE: photosensitiser is preactivated with irradiation. The biologically active points are specified herewith considering specific involved organ, its regional lymph nodes of vessels and lymph nodes, anatomic position of off-organic mains. Then the fluid photosensitiser is introduced pharmapuncture through the biologically active points or by lymphotropic and pharmapuncture method through the biologically active points. After the therapeutic concentration of the photosensitiser in the tumour is achieved, introduction point is exposed to therapeutic optical radiation.

EFFECT: method allows improving clinical effectiveness, with reducing dosage of introduced photosensitiser, reducing irradiation readiness time, preventing intoxication, ensuring collateral therapeutic effect.

2 ex

 

The invention relates to medicine, in particular clinical Oncology, and can be used for the treatment of malignant tumors and for the treatment of hypertrophic processes, inflammatory diseases (e.g., periodontal disease).

Known methods of photodynamic therapy of tumors, comprising introducing into the tumor photodynamic drug and irradiation zone of tumor growth upon reaching the photodynamic therapeutic concentrations of the drug in the tumor therapeutic optical radiation absorbed photodynamic drug (see, for example, descriptions of invention to the patent RU 2161053, IPC 7 A61N 5/06, publication date 2000.12.27; EN 2113254, IPC 6 A61N 5/06, publication date 1998.06.20).

The disadvantage of this method is low efficiency due to the applied operations introduction photodynamic tumor drug.

The closest analogue of the claimed invention is a method of photodynamic therapy of malignant tumors, including introduction into the patient photodynamic drug (photosensitizer) and irradiation of pathological region of the optical, in particular, laser radiation (see the description of the patent RU 2113254, IPC 6 A61N 5/06, publication date 1998.06.20).

Disadvantages bliges the th similar are large dosage of photosensitizers, for a long time ready to irradiation optical radiation.

The technical result of the claimed invention is expressed in increasing the efficiency of the method by optimizing the operation of introducing into the tumor photodynamic drug, lowering photodynamic doses of the drug, reducing the time ready to irradiation optical radiation.

The invention is characterized by the fact that photodynamic drug is injected in the liquid state lymphotropic by and/or pharmamedstore through biologically active points, pre-selected by the specific tumour internal organ, its regional lymph nodes, vessels and lymph nodes, anatomical location neorganic major highways.

The method of photodynamic therapy of malignant tumors is as follows. Pre-chosen biologically active points with regard to a specific internal organ, affected by the tumor. Enter photodynamic drug in a liquid state through biologically active points lymphotropic by and/or pharmamedstore in the tumor. After reaching the photodynamic therapeutic concentrations of the drug in the tumour domestic who eat the body produce radiation optical radiation. As the source of optical radiation can be applied, for example, a laser. The irradiation time, irradiation intensity is determined for each specific tumor individually by known methods.

The method of photodynamic therapy of tumors can be used:

- in benign and malignant tumors;

- tumors of the skin;

- when attrations disorders in patients with chronic venous insufficiency;

- for secondary posterization the lymphostasis of the lower extremities;

in the treatment of purulent wounds;

- papillomas, periodontitis, paradontosis, eczema, neurodermatitis.

When using this method solves one of the main problems of the development of photodynamic therapy - improving the selectivity of accumulation of photodynamic drug (photosensitizer) in the tumor; thus there is a possibility dosed sighting supply of the drug to the tumor, excluding massive necrosis and the intoxication of the organism decay products.

The principle of photodynamic therapy is as follows.

After the introduction photodynamic drug (photosensitizer) in the body of the patient and achieve therapeutic concentrations at the site of the tumor is irradiated tumor source no coherent laser or the rental radiation with a specific wavelength, corresponding to the maximum absorption of the used photosensitizer, thus there is a photochemical reaction: a photon of light interacts with a photosensitizer, causes the latter to an excited (active) state. The photosensitizer being in the active state, reacts with oxygen, passing him his energy, which leads to the formation of a new "singlet" oxygen forms. "Singlet" oxygen is a strong oxidizing processes that exceed the threshold values in diseased cells, resulting in their damage and death (in other words, the photochemical reaction leads to leaf tissue becoming necrotic and, consequently, destruction of the tumor).

The procedure of photodynamic therapy in pharmacopuncture and lymphotropic the introduction of the photosensitizer is as follows.

When lymphotropic the introduction of fotosensibilizatora the drug is injected under the skin (subcutaneous fat), where there are clusters of lymph vessels, bringing or environmental. For example, the foot between the first and second fingers in subcutaneous adipose tissue are the vessels that carry the drug (if you enter) to the kidney on the same side (proven with the introduction of methylene blue dye), (see Lymphotropic medicinal products (Tools and techniques of practical lymphology): And the structure. letter / Ministry of health of the USSR, p.20, 1987).

Description manipulation when lymphotropic therapy:

1. The doctor is an individual recipe for the patient.

2. Finds the location to which you want to enter the drug. Takes three of the syringe and through the first needle of the syringe enters the following drugs in the sequence specified:

- 0,5% novocaine or lidocaine is used for anesthesia;

- chymotrypsin (or lydasum 1 ml or heparin 1 ml) is used as infostealer that promotes the penetration of drugs predominantly in lymphatic channel, accelerate lymph flow and acts as a conduit for input after the medicinal product;

- photosensitizer (1-2 ml) (pre-activated using radiation light source with wavelength, recommended by the manufacturer of the photosensitizer within 15-20 minutes). For example, a photosensitizer type Radachlorin optimal mode of exposure is the light radiation with a wavelength of 662±3 nm at a dose of 200-500 j/cm2(instructions for use).

Upon reaching the photodynamic therapeutic concentrations of the drug (after 4-12 hours depending on the place of introduction and destination), the doctor performs the exposure of the place of introduction of the photosensitizer source laser or some of gerontolo electromagnetic radiation wavelength, the appropriate wavelength and power activation of the drug (for example, when using a photosensitizer type Radachlorin wavelength 660-662 nm, power density while exposing is 0.2-0.3 W/cm2the energy density 180-500 j/cm2). The exposure time individually to occur in a patient feeling light burning, about 15-20 minutes, but not more than 25 minutes. The doctor monitors the presence and activity of the drug on emerging fluorescence. The fluorescence radiation is recorded by a special camera with view on the monitor and is a criterion sufficient concentration of the drug and its "health".

The irradiation is then daily until the end of the glow in the introduction (from the practice 10-14 days). At the same time every day or every other day injections are made with a photosensitizer according to the developed formulation with subsequent exposure to the disappearance of the glow in the introduction.

Pharmacopuncture the introduction of the drug in the area of biologically active points (BAP) is as follows.

Pharmacopuncture - introduction of micro-doses of drugs in acupuncture points (see Agalarov L.G. Pharmacopuncture reflexology, 208 pages, published by Arnebia, 2002).

The photosensitizer is injected into the same syringe without conductors on the depths of the, specified in the Atlas BAHT, in the amount of 1-2 ml). When the photosensitizer is delivered (transported) only to the appropriate authority. In addition to the main therapeutic action of the photosensitizer includes the whole cycle of mechanisms:

1) is excited Metrocity immunity;

2) restores the energy balance of the whole body as the point selected for a particular recipe, has a therapeutic effect on the energy and material level (see, for example, Gava lovsan "Traditional and modern aspects of Eastern reflexology", M, Science, 1992 str). For example, the pain the pelvic area, the introduction of FCS in point # 30 of the stomach Meridian relieves pain in the ovary and through her FS is supplied to the ovary. Processing point leads to improved blood supply to this area (pelvic), normal menstrual cycle, if it's a woman, alleviates pain in the sigmoid colon, normal stools, if you have constipation; this same point, revealing the power of the lower extremities, resulting in the rehabilitation and prevention of impaired blood supply and innervation of the foot.

Procedure pharmacopuncture introduction is as follows.

The doctor is an individual recipe for the patient.

1. The selected point compares with the Atlas BAHT.

2. Prepares a syringe with a photosensitizer(1-2 ml) depending on the weight of the patient, activating the photosensitizer using radiation light source with wavelength, recommended by the manufacturer of the photosensitizer, for 15-20 minutes. For example, a photosensitizer type Radachlorin is the light radiation with a wavelength of 662±3 nm at a dose of 200-500 j/cm2(according to the Instructions for use of the drug).

3. Introduces the photosensitizer at the recommended depth. Depth of insertion is determined by well-known methods (see, for example, Acupuncture under the General editorship of La Quang Nien, M, Medicine, 1989, str-461).

Upon reaching therapeutic concentrations of the drug (after 4-12 hours depending on the place of introduction and destination), the doctor performs the exposure of the place of introduction of the photosensitizer by the source of laser or non-coherent electromagnetic radiation of a wavelength corresponding to the wavelength and power of the activation of the drug (for example, when using a photosensitizer type Radachlorin wavelength 660-662 nm, power density while exposing is 0.2-0.3 W/cm2the energy density 180-240 j/cm2). The exposure time individually to occur in a patient feeling light burning, about 15-20 minutes, but not more than 25 minutes). The doctor monitors the presence and activity of the drug on emerging fluorescence. Radiation f is uorescence is recorded by a special camera with view on the monitor.

3. The irradiation is then daily until the end of the glow in the introduction (from the practice 10-14 days).

4. At the same time every day or every other day injections are made with a photosensitizer according to the developed formulation with subsequent exposure to the disappearance of the glow in the introduction.

Sometimes pharmamedstore introduction coincides with lymphotropic. For example, point 2 of the liver Meridian coincides with lymphotropic introduction, but the drug is introduced there will come to the pelvic organs and the kidney from the introduction, but not to the liver through the lymphatic vessels, point 2 XII Meridian processed by the needle, gives the effect of "calming the liver".

The choice pharmaunternehmen introduction or lymphotropic injection of the photosensitizer is carried out by the physician in each case individually for each patient according to his diagnosis. The combination of pharmaunternehmen introduction lymphotropic, if necessary, leads to an even greater therapeutic effect. In addition, there is a point, which combine in themselves lymphotropic and pharmaunternehmen introduction.

Physiological effect when pharmamedstore the introduction or lymphotropic different, and when pharmamedstore is not fully understood as "substrate" point is still not decoded (see I.Z. Samosyuk, Wpisane, Acupuncture, M., "AST-prés is from the book", 2004, p.13-16), but the achieved result is not available with other methods of drug administration.

The test results of this method in clinics Chelyabinsk, Samara, Moscow has shown great efficiency and minimal risk of intoxication, which is especially important in the case of chronically debilitated patients with impaired liver function, kidneys, which excrete the products of tumor necrosis.

Thus, the principal achievement of this method is that you use a smaller dose with greater efficacy by selective application.

Thus, in normal use of photosensitizer dose is calculated for adults and children (on the example of Radachlorin) in the range of 0.2-1.0 mg (average of 0.65 mg) per 1 kg of body weight of the patient per day, total for the adult patient is about 45-70 mg per 70 kg of body weight in a single dose. It should be noted that Radachlorin is excreted mainly by metabolism in the liver (from annotations to the use of the drug).

In the proposed method, the maximum total dose of photosensitizer is composed of 10 ml of 0.3% R-RA, i.e. 35 mg/70 kg of body weight (2 times), while it is divided into 5-10 doses applied during 5-10 days 1-2 ml, when this is applied directly to the affected organ, greatly improving selectives the ü accumulation of the photosensitizer in the tumor, through the natural channels and is activated repeatedly, and taking into account the naturally created depot for a long time 10-14 days, i.e. the drug, injected a small dose, aiming is much longer and more efficiently, not overloaded liver and kidneys, in addition, not all blackened dead tissue tumor and, therefore, there are no related undesirable effects of intoxication of the organism in whole tumor breakdown products.

Practical application of the method

Example 1.

Patient 3., 58 years old, Moscow.

Diagnosis: melanoma metastases back in the mediastinal lymph nodes.

The state after the combined treatment:

In November 2002 diagnosed with melanoma pigmented nevus of left scapular region 3 levels invasie thickness up to 2 mm On Clark.

In the same year at the Institute of Oncology was conducted extensive excision of pigmented nevus.

5 February 2003 he enrolled in the Institute of Oncology for a recurrence of melanoma skin back with three tumor lymph nodes from 0.8 to 1.5 cm left axillary region. Conducted axillary lymphangectasia, on histological examination - metastases of melanoma. Conducted preventive chemotherapy arenosol 1 g 1, 2, 3 days, SD - 3,

During 2004 was observed in the cancer centre at the place of residence.

In early 2005, another follow-up about what orogeny metastases zagrodnik lymph nodes.

In 2006 took place two courses of treatment for the claimed method of photodynamic therapy of tumors for 10 days with an interval of 1 calendar month.

Lymphotropic therapy: Radachlorin at 1.0 on the media No. 7 (Sp 21 d/s, Cv-22, Cv 15, the round ligament of the liver, 13 " d/s").

The results further objective studies, including the present time, recurrence was not detected (tumor markers CEA, CA-125, CA-19,9, CA AND 15.3, the PSA is in the normal range, ultrasound overview picture of the lungs, lung CT scan is normal biochemical and clinical analyses of blood within normal limits).

Example 2.

Patient C., born in 1952

The diagnosis of acinar adenocarcinoma of 5 points on Glisson (3+2 degree) with perineural invasion.

The results of the prostate transrectal us from 19.11.06 (before first treatment):

- the volume of 30.7 cm cubic;

- Verenigde 4.3 cm;

- hypoechoic area in the right Central area with a diameter of 2.3×2,6 see

The results of the prostate transrectal us from 27.01.07 (after the first treatment, after 1 month):

- volume 26.4 cm cubic;

- Verenigde - 4.0 cm;

- hypoechoic area in the right Central area with a diameter of 1.1×0,7 see

Thus there is positive dynamics of treatment.

Patients received treatment: lymphotropic therapy-No. 20 (Cv 1, 2, 3, Tm 1, 2, 3, S30 d/s, B 26, 27).

The introduction of drugs through biologically active points easier and more convenient the other is their introduction. This method saves the hospital area. The patient can immediately return to work, if you do not need extra rest. Drugs introduced through biologically active points, show their usual therapeutic properties, but requires a lower dose, which is especially important for drugs with high toxicity, as well as for those that are characterized by rapid addiction for the sick.

Volume photodynamic drug entered through a biologically active point should be small but not too small. To determine the required amount of medication should be guided by the following: weight and thickness of the soft tissue at the location of the selected biologically active points; the distribution density of the dots on the plot introduction photodynamic drug. The thicker the layer of soft tissue, less the distribution of points on the plot, the greater the amount of photodynamic drug is introduced, and Vice versa. Known photodynamic drugs have specific physico-chemical properties and, consequently, different ways of activating and conditions (power, wavelength, time optical radiation), which defines the specific developer photodynamic drug.

Thus the m with the introduction of photodynamic drugs present economic and therapeutic effect:

1) significantly reduced the dose of the drug (at least 4 times);

2) the presence of the drug in tissues and organs visible visually (glow) up to 2 weeks after administration of the drug;

3) there is virtually no intoxication syndrome due to lysis of the tumor or tissue with a modified mitosis, and therefore there is no need hospital treatment;

4) reducing the multiplicity of the drug;

5) stimulates acupressure points, which provide additional therapeutic effect (enhancement of local cellular immunity);

6) there is no dissemination of the tumor.

The method of photodynamic therapy of tumors, comprising introducing into the tumor photosensitizer and the exposure of the place of introduction of the photosensitizer on the achievement of therapeutic concentration of the photosensitizer in the tumor therapeutic optical radiation absorbed by the photosensitizer, wherein the photosensitizer is pre-activated by irradiation, then injected in the liquid state pharmamedstore through biologically active points or lymphotropic by and pharmamedstore through biologically active points, pre-selected by the specific tumour vnutrennego, its regional lymph nodes, vessels and lymph nodes, anatomical location neorganic major highways, then irradiate the injection of the photosensitizer.



 

Same patents:

FIELD: medicine.

SUBSTANCE: integrated treatment of malignant tumour pleura involvement accompanied with exudative pleurisy is ensured with argon-plasma electrocoagulation of pleura at power 60-90 Wt and argon consumption 2.0-2.4 l/min followed with intraoperative photodynamic therapy. A photosensitiser is Photoditasine dosed 1.5 mg/kg. The irradiation involves diode laser of wavelength 662 nm and power density 300 mWt/cm2, at total energy dose 400 J/cm2. In addition, it is combined with hyperthermic intrapleural chemoperfsion of cisplatin 100 mg in 1500-3000 ml of 0.9 % sodium chloride solution at temperature 42°C within 60 minutes at feed rate 1200 ml/min.

EFFECT: reduced tumour weight, terminated exudation and protein loss, reduced inflammation, intoxication and pain syndrome, local and systemic cytostatic action of cisplatin.

3 ex

FIELD: medicine.

SUBSTANCE: preparation inhibiting malignant tumour development contains dis-A-fibrin and may inhibit malignant tumours by inhibiting distribution and migration of malignant tumour cells thereby may inhibit malignant tumour development.

EFFECT: inhibition of tumour invasion and dissemination.

8 cl, 4 ex, 2 tbl, 9 dwg

FIELD: medicine.

SUBSTANCE: 1-3-fold amount of water is added to mixed five-seven-year old ginseng with further treatment at pressure 1.20 to 1.50 kg/cm2 if ginseng is rind, or 2.30 to 3.00 kg/cm2 if ginseng is covered with rind at 110-130°C during 1 to 5 hours to produce treated ginseng thereafter extracted with mixed methanol and methylene chloride in ratio 0.6:1.40 to 1.2:0.8 by boiling extraction method with using a backflow condenser during 1 hour to approximately two days. The mixture is filtered that is followed with filtrate concentration and drying. The pharmaceutical composition for treatment or prevention of stomach, liver, lung, skin or breast cancer contains ginseng extract. Foodstuff contains ginseng extract.

EFFECT: product with high content of ginsenoside Rg5.

6 cl, 3 ex, 3 tbl, 14 dwg

FIELD: medicine; veterinary science.

SUBSTANCE: prevention of carcinogenic action of diethyl nitrosamine in experimental animals is ensured by daily introduction of anticarcinogen combined with feed. Anticarcinogen is presented with powdered phytoadaptogen "Chagovit" dosed 50 mg/kg within 9 months. On the 5th day, this therapy is added with introduction of diethyl nitrosamine combined with drink dosed 100 mg/l within the first 4 months.

EFFECT: lower rate of neoplastic changes in liver and oesophagus tissues, higher lifetime and survival rate of animals ensured by lower level of lipid peroxidation and improved activity of antioxidant enzymes.

2 ex, 2 tbl, 8 dwg

FIELD: medicine.

SUBSTANCE: there is disclosed pharmaceutical product as prepared solution. The pharmaceutical product comprises a reservoir filled with dissolved zoledronic acid or its pharmaceutically acceptable salt. At least the internal surface of said reservoir contains plastic material that is polyolefin. The product is exposed to thermal sterilisation, preferentially to moist thermal sterilisation. Besides the product can contain a buffer component, preferentially the buffer organic base. Additionally, the product can contain an isotonic component, preferentially mannitol. The invention provides product sterilisation at high temperature 121°C during 150 minutes without visible deformations and damages of sealed integral reservoir, as well as decomposition of pharmaceutical substance.

EFFECT: thermal stability allows for multiple sterilisation cycle that leads to sterility assurance level at least 10-12.

38 cl, 19 ex

FIELD: medicine.

SUBSTANCE: invention refers to medical products and concerns pharmaceutical composition for treatment of the diseases associated with urokinase activator of plasminogen (u-PA) and/or with receptor of activator of urokinase plasminogen (u-PAR), containing: (i) amidino-, hydroxyamidino-, guanydino- and/or hydroxyguanydinophenylalanine derivative as an active material, (ii) mixed alcohol and polyol, and (iii) aqueous phase containing buffer solution. There is also disclosed stabilisation method of pharmaceutical composition.

EFFECT: physical and chemical stability.

25 cl, 6 dwg, 1 tbl, 9 ex

FIELD: medicine.

SUBSTANCE: according to the invention, method involves introduction of Paramycin 42 ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779). In addition, the invention refers to applications of CCI-779 in producing a medicinal agent for amphicyte lymphoma.

EFFECT: application of the invention ensures amphicyte lymphoma treatment.

9 cl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medical products, particularly to application of compound of formula I where A stands for O, R stands for hydrogen or lower alkyl, and Z stands for O to prepare a medicinal agent for treatment of cancer disease chosen from primary cancer of Fallopian tube; primary peritoneal cancer and colorectal cancer progressing after Irinotecan therapy. Besides the invention concerns the pharmaceutical composition including specified compound, therapy of specified diseases and commercial package. formula (I).

EFFECT: agent is characterised with improved effectiveness.

13 cl, 7 ex

FIELD: medicine.

SUBSTANCE: there is described oral pharmaceutical composition containing 9,10-dehydroepothilone combined with a pharmaceutically acceptable carrier. According to the second version, the oral pharmaceutical composition contains trans-9,10-degihydroepothilone D and a pharmaceutically acceptable carrier containing hydroxypropyl-β-cyclodextrine, ethanol and propylene glycol. The concentrate for injection contains 9,10-degihydroepothilone D in the pharmaceutically acceptable carrier.

EFFECT: good bioavailability of epothilone D.

21 cl, 4 ex

FIELD: medicine.

SUBSTANCE: prevention of carcinogenic action of diethyl nitrosamine in experimental animals is ensured by introduction of kaskorutol dosed 0.4 g/kg within 9 months as an anticarcinogen, while diethyl nitrosamine is introduced in a dose 100 mg/l 5 days after introduction of kaskorutol within 4 months.

EFFECT: reduced carcinogenic action of diethyl nitrosamine due to inhibition of blastomogenic process, lowered level of lipid peroxidation, improved activity of antioxidant enzymes.

2 tbl, 8 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: sclera rupture is coated with conjugate covalent-bound chlorine e6 with human albumin in molar ratio 1:2.5 thus covering the surrounding tissues 1-2 mm. Thereafter, the sclera rupture region is exposed to continuous scan laser light of power 500 mWt within 1-2 minutes with coated conjugate. The wavelengths relates to maximum light absorption of chlorine e6.

EFFECT: reliable closure of rupture, prevention of sclera deformation, lower risk of infectious complications.

1 ex

FIELD: medicine.

SUBSTANCE: light guides are inserted into neoplasm transsclerally by an adjustable lanceolate needle and cannulas 23G or 25G perpendicularly to sclera on a line of the greatest diametre of the base and on a line perpendicular diametre at the distance 2.5-3.5 mm in both sides from the centre of tumour base. The depth of light guide insertion is specified from preliminary ultrasound: tumour height at the distance 2.5-3.5 mm on sclera from the centre of tumour basis minus 1.5-2 mm.

EFFECT: possibility for controlled depth hyperthermia, minimum injury of structures and eye tissues in light guide insertion and procedure, elimination of required additional surgeries following hyperthermia, necrosis limitation by tumour volume.

1 ex

FIELD: medicine.

SUBSTANCE: contact irradiation of eye tissues within photodynamic therapy involved in infectious corneal ulcers is ensured by application of a light guide nozzle with a circular border at its bottom. Application and exposition of a photosensitiser is followed with application of a staining agent on the nozzle edge. Then the nozzle is placed on the corneal ulcer region that is followed with contact laser irradiation with fields of diametre 3 mm herewith covering the adjacent fields by 5-10% of the area. The nozzle is sequentially circled within the corneal ulcer region from periphery to the middle.

EFFECT: possibility to limit the area of one laser radiation spot with specified dimensions, thus maintaining the constant distance of the light guide end face to the irradiated surface during procedure, achieved accurate visualisation of the irradiated regions, limited area of laser irradiation by desired region, managed infectious processes, epithelised corneal ulcers with forming the smooth opacity, and prevented inflammatory complications.

FIELD: medicine.

SUBSTANCE: integrated treatment of malignant tumour pleura involvement accompanied with exudative pleurisy is ensured with argon-plasma electrocoagulation of pleura at power 60-90 Wt and argon consumption 2.0-2.4 l/min followed with intraoperative photodynamic therapy. A photosensitiser is Photoditasine dosed 1.5 mg/kg. The irradiation involves diode laser of wavelength 662 nm and power density 300 mWt/cm2, at total energy dose 400 J/cm2. In addition, it is combined with hyperthermic intrapleural chemoperfsion of cisplatin 100 mg in 1500-3000 ml of 0.9 % sodium chloride solution at temperature 42°C within 60 minutes at feed rate 1200 ml/min.

EFFECT: reduced tumour weight, terminated exudation and protein loss, reduced inflammation, intoxication and pain syndrome, local and systemic cytostatic action of cisplatin.

3 ex

FIELD: medicine.

SUBSTANCE: therapy involves exposure on acupunctural points of gall bladder in combination with conventional conservative therapy. Exposure on acupunctural points implies laser radiation of frequency 1425-1575 Hz, wavelength 0.83-0.89 mcm, unit impulse power 5-6 Wt, unit impulse duration 110-160 ns. Acupunctural points are tonic by exposure within 4-6 seconds, while sedation is ensured by exposure within 16-18 seconds. Then right hypochondrium is exposed to pulse magnetic field of induction 22.5-37.5 mTl, frequency 49.5-50.5 Hz, duration 20-25 minutes. The epigastrium is exposed to variable magnetic field of induction 22.5-37.5 mTl, frequency 49.5-50.5 Hz, and duration 20-25 minutes. The therapeutic course is 10-12 days.

EFFECT: method reduces fatal outcome rate ensured by exacerbation management and elective surgery.

2 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: said device contains a transparent cylindrical support case, a retainer ring and a lock nut. The support case comprises a necked top with an external thread and a light guide port, and a hollow bottom with a circular marking edge at the end face. When the device is applied for photodynamic therapy of intraocular neoplasms, the marking edge is covered with brilliant green. The device is mounted with its end face of the bottom with a marking edge on sclera exposed to contact transscleral laser irradiation herewith covering the adjacent fields by 15-20% of the area through sequential relocation of the device from periphery to the middle within projection of tumour base on sclera and covering 2 mm of adjacent tissues.

EFFECT: application of group of inventions provides limitation of the area of one laser radiation spot in specified dimensions, herewith maintaining constant distance of the light guide end face to irradiated surface within procedure, accurate visualisation of the irradiated sites, with limiting the area of a laser irradiation by desired region.

2 cl, 1 dwg

FIELD: medicine.

SUBSTANCE: invention concerns medicine, particularly obstetrics and hestosis treatment for the pregnant. Method involves endovascular laser irradiation of blood for six days. Further, polyphepan is administered internally for eight days in the dosage of 0.5 g per kg of pregnant body weight for 3-4 times per day.

EFFECT: therapeutic effect with reduced treatment duration and medication load on organism of the pregnant due to the selected regimen.

1 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, laser medicine, and can be applied in treatment of trophic ulcers of venous etiology. Method involves processing of ulcer surface and skin around ulcer by air and gas flow with nitrogen oxide content 2000 ppm or more at 40°C, with 10 second exposition per 1 cm2. Further, 0.1% Radachlorine gel is applied as photo sensitiviser in amount of 0.2 g per 1 cm2 with 60 minutes exposition. Then laser emission of 0.665 mcm wavelength and light energy dosage of 150-200 J/cm2 is applied at 3-5 mm distance from wound surface. Afterwards intravenous blood irradiation is performed over cubital vein by laser emission of 0.632 mcm wavelength and radiation power of 5 mW with 15 minutes exposition. Treatment course comprises 10 daily procedures of air and gas flow processing and intravenous blood irradiation and 5-8 photodynamic therapy procedures performed over 2 day interval.

EFFECT: improved neurotrophic regulation of damaged tissues, antimicrobe effect, reduced frequency of purulent complications, improved blood flow properties, prevented resistance of ulcer microflora to antibiotics and drugs, prevented dysplasia, cicatrical changes and skin malignisation around trophic ulcer.

4 cl, 1 ex

FIELD: medical equipment.

SUBSTANCE: invention concerns medical equipment and can be applied in cancer tissue treatment in various organs of biological objects. Device includes semiconductor laser diode, clock generator, semitransparent mirror, comparator, first, second and third direct current amplifiers, differentiating amplifier, discriminating amplifier, first and second photo receivers, delay line, analog to digital converter, programmed permanent memory, first and second binary code comparators, first and second control systems of secondary power sources, first and second secondary power sources and light panel/indicator. Biological object is positioned in line between semiconductor laser, semitransparent mirror and second photo receiver.

EFFECT: extended range of technical devices for laser cancer therapy.

4 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to laser therapy. The first stage of the therapy involves introduction of medicines and intravenous laser blood exposure by installing a needle in one solution transfusion system for quartz fibre of diametre 0.7 mm through which the patient is exposed to helium-neon laser of power 1.2 mW at exposition 90 minutes within seven daily procedures. The second stage includes paravertebral block within herniated disk localisation in projection of herniated disk. Quartz fibre of diametre 0.7 mm is introduced through a puncture needle to the level of surface musculofascial layer. Injection of solution is immediately followed with irradiation with helium-neon laser of power 1.2 mW at exposition 80 minutes within seven daily procedures. Medicines within solution transfusion system are as follows: Trental 5 ml, Actovegin 5 ml, 15% Xantinol Nicotinate 2 ml, vitamin B1 2 ml alternated with vitamin B6 2 ml, 5% vitamin C 3 ml dissolved in physiologic saline 150 ml. Paravertebral block of the first day includes 5% glucocorticoid Diprospan 1 ml combined with 2% Lidocaine. For the following days 2% Lidocaine is used.

EFFECT: method allows terminating inflammatory process, ensuring stable pain management.

3 ex

FIELD: medicine.

SUBSTANCE: invention pertains to medicine, surgery and may be used for hemostasis in pyloroduodenal ulcers when there is no clear visualisation of the source of bleeding. Endoscopic examination of the pyloroduodenal zone is done followed by consecutive injection of solution of vasoconstrictor. Injection points are selected from 6 points of pylorus at 1, 3, 5, 7, 9, and 11 hours of the reference clock-face. A point located in the central part of the upper wall of pylorus is accepted for 12 hours. With the source of bleeding located on the front wall of the bulb DNA injections are made into pylorus points corresponding to 7,9,11 hours of the reference clock-face. With the source of bleeding located on the upper wall of the bulb DNA injections are made into pylorus points corresponding to 1 and 11 hours of the reference clock-face. With the source of bleeding located on the back wall of the bulb DNA injections are made into pylorus points corresponding to 1,3,5 hours of the reference clock-face. With the source of bleeding located on the lower wall of the bulb DNA injections are made into pylorus points corresponding to 5 and 7 hours of the reference clock-face.

EFFECT: use of the method decreases number of complications through clear visualisation of the source of bleeding.

3 dwg, 4 ex

Up!